<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922452</url>
  </required_header>
  <id_info>
    <org_study_id>CV006-028</org_study_id>
    <nct_id>NCT02922452</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects</brief_title>
  <official_title>An Open-Label, Single-Sequence Study to Evaluate the Effect of Diltiazem on the Single-Dose Pharmacokinetics of BMS-986141 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effect of dilitazem on the single-dose PK of BMS-986141 with&#xD;
      parameters like Cmax, AUC(INF), and AUC(0-T).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Days 1-21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))</measure>
    <time_frame>Days 1-21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC (0-T))</measure>
    <time_frame>Days 1-21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and death</measure>
    <time_frame>Screening- until 30 days after discontinuation of dosing or subject's participation in the study if the last]</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>BMS-986141 and Dilitazem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986141</intervention_name>
    <description>Single dose BMS-986141 and Multiple doses of Dilitazem</description>
    <arm_group_label>BMS-986141 and Dilitazem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilitazem</intervention_name>
    <description>Single dose BMS-986141 and Multiple doses of Dilitazem</description>
    <arm_group_label>BMS-986141 and Dilitazem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent&#xD;
&#xD;
          2. Healthy men and women (not of child bearing potential) as determined by medical&#xD;
             history, surgical history, physical examination, vital signs, electrocardiogram (ECG),&#xD;
             and clinical laboratory tests including coagulation parameters.&#xD;
&#xD;
          3. Subjects with body mass index of 18 to 32 kg/m2, inclusive.&#xD;
&#xD;
          4. Women participants must have documented proof that they are not of childbearing&#xD;
             potential.&#xD;
&#xD;
          5. Men who are sexually active with WOCBP must agree to follow instructions for method(s)&#xD;
             of contraception for the duration of treatment with BMS-986141 plus 5 half-lives plus&#xD;
             90 days for a total of 100 days post-treatment completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute or chronic medical illness, subjects with bleeding diathesis, gastrointestinal&#xD;
             ulcer, hepatic disease.&#xD;
&#xD;
          2. History of nausea, diarrhoea, recent surgery, use of tobacco or nicotine containing&#xD;
             products, drug or alcohol use, important arrhythmias, sinus bradycardia, chronic&#xD;
             headaches, history of multiple events of dizziness, periodontal disease and recent&#xD;
             blood donation.&#xD;
&#xD;
          3. Prior exposure to BMS-986141 or prothrombin complex, any investigational product or&#xD;
             placebo within 4 weeks of study treatment start, any prescription or over the counter&#xD;
             drugs except those cleared by BMS clinical monitor.&#xD;
&#xD;
          4. History of allergy to BMS-986141, dilitazem or any other significant drug allergy or&#xD;
             adverse reaction to anticoagulants or antiplatelets.&#xD;
&#xD;
          5. Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, ECGs, or clinical laboratory determinations beyond&#xD;
             what is consistent with the target population&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

